腹腔热灌注联合静脉化疗治疗晚期卵巢癌的临床研究

Clinical Study of Intraperitoneal Hyperthermia Combined with Intravenous Chemotherapy in the Treatment of Advanced Ovarian Cancer

目的探讨腹腔热灌注联合静脉化疗治疗晚期卵巢癌的临床效果。方法方便选取该院2011年12月—2015年112月收治的50例卵巢癌晚期恶性腹水患者,随机将其分为两组,每组25例。治疗组采用紫杉醇静脉化疗+奈达铂腹腔灌注化疗治疗,对照组使用紫杉醇联合奈达铂静脉治疗。观察两组患者的腹水控制率及不良反应。结果结果显示,治疗组的腹水控制率为88%明显高于对照组的76%,差异有统计学意义(χ2=6.971,P=0.001)。不良反应上,观察组腹痛、恶心、呕吐、骨髓抑制以及腹泻的发生率分别为52%、48%、26%、12%以及8%,于对照组的64%、60%、32%、16%、12%比较,差异无统计学意义(χ2腹痛=0.031,P=0.964;χ2恶心=0.036,P=0.961;χ2呕吐=0.027,P=0.952;χ2骨髓抑制=0.022,P=0.874;χ2腹泻=0.051,P=0.853)。结论使用腹腔热灌注联合静脉化疗的方法可以有效控制晚期卵巢癌患者的恶性腹腔积液和不良反应,具有良好的治疗效果。

Objective To investigate the clinical effect of intraperitoneal hyperthermia combined with intravenous chemotherapy in the treatment of advanced ovarian cancer. Methods 50 patients with advanced malignant ascites who were admitted to the hospital between December 2011 and December 2015 were convenient selected. They were randomly divided into two groups, 25 cases in each group. The treatment group was treated with paclitaxel intravenous chemotherapy and nedaplatin intraperitoneal infusion chemotherapy. The control group was treated with intravenous paclitaxel and nedaplatin.The ascites control rate and adverse reactions were observed in both groups. Results The control rate of ascites in the treatment grou88%p was significantly higher than that of the control group 76%. The difference was statistically significant（χ^2=6.971, P=0.001）. In adverse reactions, the incidences of abdominal pain, nausea, vomiting, bone marrow suppression, and diarrhea in the observation group were 52%, 48%, 26%, 12%, and 8%, respectively, in the control group, 64%, 60%, 32%,and 16%, 12%, the difference was not significant（χ2 abdominal pain=0.031, P= 0.964; χ^2 nausea=0.036, P= 0.961; χ^2 vomiting=0.027, P=0.952; χ^2 bone marrow auppression=0.022, P =0.874; χ2 diarrhea =0.051, P =0.853）. Conclusion The use of intraperitoneal hyperthermia combined with intravenous chemotherapy can effectively control malignant ovarian ascites and adverse reactions in patients with advanced ovarian cancer, and has a good therapeutic effect.